Literature DB >> 8065700

Fluconazole in the management of fungal ocular infections.

S F Urbak1, T Degn.   

Abstract

The number of fungal infections has increased dramatically, and those involving the eye pose a serious problem and treatment challenge to practicing physicians. Despite the overall effectiveness of conventional treatment with amphotericin B, there are several well-recognized disadvantages associated with this drug. The topical agent natamycin, although effective against the filamentous fungi, is less effective against Candida species. Ketoconazole, an effective broad-spectrum, oral antifungal, possesses a better safety profile than amphotericin B, but is also associated with potential toxicity and drug interactions. The ongoing search for improved antifungal compounds led to the development of fluconazole. This review article focuses on fluconazole in the treatment of patients with fungal infections of the eye. In addition to its proven effectiveness and safety in patients with various mycoses, the pharmacokinetic profile of fluconazole confers many advantages including diffusion into ocular tissue. A number of reported cases document the effectiveness of this triazole in human ocularmycoses without the occurrence of significant side effects.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8065700     DOI: 10.1159/000310473

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  7 in total

1.  Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses.

Authors:  D Debruyne
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

2.  Clinical results of topical fluconazole for the treatment of filamentous fungal keratitis.

Authors:  Sergio Sonego-Krone; Daniel Sanchez-Di Martino; Rosa Ayala-Lugo; Guillermo Torres-Alvariza; Christopher N Ta; Luciene Barbosa; Herminia Miño de Kaspar
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-08-18       Impact factor: 3.117

3.  Fluconazole treatment of candidal infections caused by non-albicans Candida species.

Authors:  J W van 't Wout
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-03       Impact factor: 3.267

Review 4.  Tissue penetration of antifungal agents.

Authors:  Timothy Felton; Peter F Troke; William W Hope
Journal:  Clin Microbiol Rev       Date:  2014-01       Impact factor: 26.132

5.  Large-scale multicentre study of fluconazole in the treatment of hospitalised patients with fungal infections. Multicentre European Study Group.

Authors:  P F Troke
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-04       Impact factor: 5.103

6.  Late-onset fungal interface keratitis following endothelial keratoplasty with positive donor fungal culture.

Authors:  Kenneth A Beckman; Mark S Milner; Parag A Majmudar; Jodi I Luchs
Journal:  Am J Ophthalmol Case Rep       Date:  2020-04-17

7.  Candida parapsilosis keratitis treated successfully with topical and oral fluconazole.

Authors:  Pei-Hsuan Li; Chun-Chen Chen; Shiow-Wen Liou
Journal:  Taiwan J Ophthalmol       Date:  2016-06-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.